Safer Choice Standard

SDS Number: 00010329001 Revision Date: 1/2/2018
11. Toxicological Information
EFFECT OF OVEREXPOSURE - INHALATION: Under normal use conditions, this product is not expected to cause adverse health
effects. Inhalation of vapors in high concentration may cause mild irritation of respiratory system (nose, mouth, mucous membranes).
EFFECT OF OVEREXPOSURE - SKIN CONTACT: Under normal use conditions, this product is not expected to cause adverse
health effects. Prolonged or repeated contact with skin may cause mild irritation.
EFFECT OF OVEREXPOSURE - EYE CONTACT: Under normal use conditions, this product is not expected to cause adverse
health effects. Direct eye contact may cause irritation.
EFFECT OF OVEREXPOSURE - INGESTION: Under normal use conditions, this product is not expected to cause adverse health
effects. Single dose oral toxicity is very low. Amounts ingested incidental to industrial handling are not likely to cause injury; however,
ingestion of large amounts may cause injury.
CARCINOGENICITY: No Information
EFFECT OF OVEREXPOSURE - CHRONIC HAZARDS: Repeated or prolonged exposure may cause mild irritation of eyes and
skin. The International Agency for Research on Cancer (IARC) has determined that crystalline silica in the form of quartz or
cristobalite that is inhaled from occupational sources is carcinogenic to humans (Group 1- carcinogenic to humans). Refer to IARC
Monograph 68, Silica, Some Silicates and Organic Fibres (published in June 1997) in conjunction with the use of these materials. The
National Toxicology Program (NTP) classifies respirable crystalline silica as "known to be a human carcinogen". Refer to the 9th
Report on Carcinogens (2000). The American Conference of Governmental Industrial Hygienists (ACGIH) classifies crystalline silica,
quartz, as a suspected human carcinogen (Group A2). Breathing dust containing respirable crystalline silica may not cause
noticeable injury or illness even though permanent lung damage may be occurring. Inhalation of dust may have the following serious
chronic health effects: Excessive inhalation of respirable dust can cause pneumoconiosis, a respiratory disease, which can result in
delayed, progressive, disabling and sometimes fatal lung injury. Symptoms include cough, shortness of breath, wheezing, non-
specific chest illness and reduced pulmonary function. Smoking exacerbates this disease. Individuals with pneumoconiosis are
predisposed to develop tuberculosis. There is some evidence that breathing respirable crystalline silica or the disease silicosis is
associated with an increased incidence of significant disease endpoints such as scleroderma (an immune system disorder manifested
by fibrosis of the lungs, skin and other internal organs) and kidney disease.
PRIMARY ROUTE(S) OF ENTRY: Inhalation, Skin Contact
Acute Toxicity Values
The acute effects of this product have not been tested. Data on individual components are tabulated below
CAS-No.
Chemical Name Oral LD50 Dermal LD50 Vapor LC50
1317-65-3 Limestone 6450 mg/kg Rat >2000 mg/kg >20 mg/L
8042-47-5 White mineral oil >5000 mg/kg Rat 2000 mg/kg Rabbit >20 mg/L
13463-67-7 Titanium dioxide >10000 mg/kg Rat >5000 mg/kg Rabbit >20 mg/L
14808-60-7 Quartz 500 mg/kg Rat >2000 mg/kg >20 mg/L
N.I. = No Information
12. Ecological Information
ECOLOGICAL INFORMATION: Ecological injuries are not known or expected under normal use.
13. Disposal Information
DISPOSAL INFORMATION: No Information
14. Transport Information
SPECIAL TRANSPORT PRECAUTIONS: No Information
DOT UN/NA Number: N.A.
DOT Proper Shipping Name: Not Regulated
DOT Technical Name: N.A.
DOT Hazard Class: N.A.
Hazard SubClass: N.A.
Packing Group: N.A.
Page 4 / 6